1. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc . 1996;71:576-586. doi: 10.4065/71.6.576
2. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia . 2014;55:475-482. doi: 10.1111/epi.12550.
3. Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality. Epilepsia . 2008;49:8-12. doi: 10.1111/j.1528-1167.2008.01443.x
4. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology . 1991;41:965-972. doi: 10.1212/wnl.41.7.965
5. Ropper AH. Transient global amnesia. N Engl J Med . 2023;388:635-540. doi: 10.1056/NEJMra2213867
6. Bouma HK, Labos C, Gore GC, et al. The diagnostic accuracy of routine electroencephalography after a first unprovoked seizure. Eur J Neurol . 2016;23:455-463. doi: 10.1111/ene.12739
7. Narayanan JT, Labar DR, Schaul N. Latency to first spike in the EEG of epilepsy patients. Seizure . 2008;17:34-41. doi: 10.1016/j.seizure.2007.06.00 3
8. Salmenpera TM, Duncan JS. Imaging in epilepsy. J Neurol Neurosurg Psychiatry . 2005;76:iii2-iii10. doi: 10.1136/jnnp.2005.075135
9. Jackson GD, Berkovic SF, Tress BM , et al. Hippocampal sclerosis can be reliably detected by magnetic resonance imaging. Neurology . 1990;40:1869-1875. doi: 10.1212/wnl.40.12.1869
10. Bonnett LJ, Kim, L, Johnson A, et al. Risk of seizure recurrence in people with single seizures and early epilepsy - model development and external validation. Seizure . 2022;94:26-32. doi: 10.1016/j.seizure.2021.11.007
11. Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology . 2015;84:1705-1713. doi: 10.1212/WNL.0000000000001487
12. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and terminology. Epilepsia . 2017;58:522-530. doi: 10.1111/epi.13670
13. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsy: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia . 2010;51:676-685. doi: 10.1111/j.1528-1167.2010.02522.x
14. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblinded randomized controlled trial. Lancet . 2007;369:1016-1026. doi: 10.1016/S0140-6736(07)60461-9
15. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomized controlled trial. Lancet 2007;369:1000-1015. doi: 10.1016/S0140-6736(07)60460-7
16. Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalized and unclassified epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomized controlled trial. Lancet . 2021;397:1375-1386. doi: 10.1016/S0140-6736(21)00246-4
17. Mawhinney E, Craig J, Morrow J. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology . 2013;80:400-405.
18. Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomized controlled trial. Lancet . 2021;397:1363-1374. doi: 10.1016/S0140-6736(21)00247-6
19. Smith PE. Initial management of seizure in adults. N Engl J Med . 2021;385:251-263. doi: 10.1056/NEJMcp2024526
20. Depakene (valproic acid). Package insert. Abbott Laboratories; 2011. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2011/018081s046_18082s031lbl.pdf
21. Greenberg RG, Melloni C, Wu H, et al. Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach. Clin Neuropharmacol . 2016;39:232-240. doi: 10.1097/WNF.0000000000000172
22. Lamictal (lamotrigine). Package insert. GlaxoSmithKline; 2009. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2009/020241s037s038,020764s030s031lbl.pdf
23. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA . 2004;291:605-614. doi: 10.1001/jama.291.5.605
24. Topamax (topiramate). Package insert. Janssen Pharmaceuticals, Inc. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2012/020844s041lbl.pdf
25. Keppra (levetiracetam). Package insert. UCB, Inc.; 2009. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2009/021035s078s080%2C021505s021s024lbl.pdf
26. Carbatrol (carbamazepine). Package insert. Shire US Inc; 2013. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2013/020712s032s035lbl.pdf
27. Neurontin (gabapentin). Package insert. Pfizer; 2017. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf
28. Zonegran (zonisamide). Package insert. Eisai Inc; 2006. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2006/020789s019lbl.pdf
29. Gloss D, Paragon K, Pack A, et al. Antiseizure medication withdrawal in seizure-free patients: practice advisory update. Report of the AAN Guideline Subcommittee. Neurology . 2021;97:1072-1081. doi: 10.1212/WNL.0000000000012944
30. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med . 2000:342:314-319. doi: 10.1056/NEJM200002033420503
31. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia . 2010;51:1069-1077. doi: 10.1111/j.1528-1167.2009.02397.x
32. Leppik IE. Compliance during treatment of epilepsy. Epilepsia 1988;29(suppl 2):S79-S84.
33. S utter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: a systematic review. Neurology . 2015;13;85:1332-1341. doi: 10.1212/WNL.0000000000002023
34. Singh G, Rees JH, Sander JW. Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. JNNP. 2007;78:342-349. doi: 10.1136/jnnp.2006.106211
35. Pisani F, Oteri G, Costa C., et al. Effects of psychotropic drugs on seizure threshold. Drug Safety . 2002;25:91-110.
36. Rossi KC, Joe J, Makhjia M, et al. Insufficient sleep, electroencephalogram activation, and seizure risk: re-evaluating the evidence. Ann Neurol . 2020;86:798-806. doi: 10.1002/ana.25710
37. Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep for a healthy adult: a Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep . 2015;38:843-844. doi: 10.5665/sleep.4716
38. Höppener RJ, Kuyer A, van der Lugt PJ. Epilepsy and alcohol: the influence of social alcohol intake on seizures and treatment in epilepsy. Epilepsia . 1983;24:459-471. doi: 10.1111/j.1528-1157.1983.tb04917.x
39. Keeler MH, Reifler CB. Grand mal convulsions subsequent to marijuana use. Case report. Dis Nerv Syst . 1967:28:474-475.
40. Epidiolex (cannabidiol). Package insert. Greenwich Biosciences Inc; 2018. Accessed September 27, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
41. ClinicalTrials.gov. Maternal Outcomes and Neurodevelopmental Effects of Antiseizure Drugs (MONEAD). Accessed September 24, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT01730170
42. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology . 2006;67:407-412. doi: 10.1212/01.wnl.0000227919.81208.b2
43. Meador K, Reynolds MW, Crean S. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res . 2008;81:1-13. doi:10.1016/j.eplepsyres.2008.04.022
44. Marxer CA, Rüegg S, Rauch MS, et al. A review of the evidence on the risk of congenital malformations and neurodevelopmental disorders in association with antiseizure medications during pregnancy. Expert Opin Drug Saf . 2021;20:1487-1499. doi: 10.1080/14740338.2021.1943355
45. Asadi-Pooya AA, Sperling MR. Epidemiology of psychogenic nonepileptic seizures. Epilepsy Behav. 2015;46:60-65. doi: 10.1016/j.yebeh.2015.03.015
46. Beimer NJ, LaFrance Jr WC. Evaluation and treatment of psychogenic nonepileptic seizures. Neurol Clin . 2022;40:799-820. doi: 10.1016/j.ncl.2022.03.017
4 7. Motamedi GK. Psychogenic nonepileptic seizures: a disconnect between body and mind. Epilepsy Behav. 2018;78:293-294. doi: 10.1016/j.yebeh.2017.10.016
48. Chang AK , Shinnar S. Nonconvulsive status epilepticus. Emerg Med Clin North Am . 2011;29:65-72. doi: 10.1016/j.emc.2010.08.006
49. AAP Practice Guideline. Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics . 2011;127:389-394. doi: 10.1542/peds.2010-3318
50. Chin RF, Neville BG, Peckham C, et al. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet . 2006;368:222-229. doi: 10.1016/S0140-6736(06)69043-0
51. McTague A, Martland T, Appleton R. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Sys Rev . 2018;1(1):CD001905. doi: 10.1002/14651858.CD001905.pub3
52. Jensen FE. Epilepsy as a spectrum disorder: implications from novel clinical and basic neuroscience. Epilepsia . 2011;52(suppl 1):1-6. doi: 10.1111/j.1528-1167.2010.02904.x
53. Kass JS, Rose RV. Driving and epilepsy: ethical, legal, and health care policy challenges. Continuum (Minneap Minn). 2019;25:537-542. doi: 10.1212/CON.0000000000000714
54. Troxell J. Epilepsy and employment: the Americans with Disabilities Act and its protections against employment discrimination. Med Law . 1997;16:375-384.